Investing in the future of health

Promoted content

In a bid to highlight the important yet highly delicate nature of Europe’s innovative industries, a new report, produced by the Deloitte Health Economics Group and commissioned by Janssen, has sought to evaluate the comparable risks incurred across five major industries.

It reveals that, compared to other innovative sectors such as automotive, commercial aircraft, and consumer electronics, the biopharmaceutical sector experience the greatest degree of risk and uncertainty in terms of its substantial R&D investments, lengthy product development cycles, and due to the complex regulatory hurdles that create barriers to patient access.

The report raises a number of questions and we hope it will stimulate a debate which recognises real health needs and prioritises areas for innovation that identifies affordability for payers and for patients, and is aware of the need for risk mitigation and risk sharing.

Subscribe to our newsletters